Market News
4 min read | Updated on January 13, 2025, 13:27 IST
SUMMARY
Shares of PCBL were trading 8.21% lower at ₹359 apiece on the NSE. The company's net profit dropped 37% on-year to ₹93 crore in the October-December quarter, sharply lower than the ₹148 crore that it clocked in the same period last year. The decline in the company's bottom line was largely driven by a spike in operating costs.
At 1:12 PM, the S&P BSE SENSEX was trading at 76,644.53, down 734.38 points, or 0.95%.
At 1:12 PM, the S&P BSE SENSEX was trading at 76,644.53, down 734.38 points, or 0.95%, while the NSE's NIFTY50 index was trading at 23,174.75, down 256.75 points, or 1.1%.
Hindustan Petroleum dropped more than 7% to hit a low of ₹360.15 per share on the NSE. The stock later trimmed losses to trade at ₹370, down by 4.75% over the last close.
The country’s largest oil retailer, Indian Oil Corporation, also declined over 5% to a day low of ₹123.60 per share on the NSE.
The company reported a 4.8% rise in its consolidated net profit to ₹723.54 crore for the third quarter ended December 2024.
The company had posted a net profit of ₹ 690.41 crore a year ago.
Last seen, the stock was trading at ₹3585.90, down 2.71% on the BSE.
Biocon Biologics Limited (BBL) is a subsidiary of Biocon.
Shares of the company, reacting to the development, on Monday, January 13, surged as much as 4.58% to ₹377.50 apiece on the NSE.
According to the FDA, a voluntary action indicated (VAI) classification means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
Last seen, the stock was trading at ₹366.15, up 1.44%.
On Friday, the stock settled at ₹1,034.60. The scrip's 52-week low level is ₹769.85, which was touched on March 20, 2024.
The real estate company bought 16.12 acres of land in Gurugram for nearly ₹300 crore to develop a housing project, as it remains bullish on demand for mid-income and premium residential properties.
The land is located on Sector 71, Southern Peripheral Road, Gurugram, Haryana.
"We have purchased a 16-acre land parcel in Gurugram for the development of a premium housing project," Signature Global Chairman Pradeep Kumar Aggarwal told PTI.
The company's net profit dropped 37% on-year to ₹93 crore in the October-December quarter, sharply lower than the ₹148 crore that it clocked in the same period last year. The decline in the company's bottom line was largely driven by a spike in operating costs.
In December 2024, Piramal Pharma said it would pay $407,400 to US-based VetDC, Inc to settle a dispute over rejected batches of a product.
Piramal Pharma Solutions Inc, a unit of the company, and VetDC, Inc have entered into a settlement agreement for an amount of USD 407,400, the drugmaker said in a regulatory filing.
VetDC had claimed damages on account of the rejection of certain batches of products manufactured and supplied by Piramal Pharma Solutions Inc.
About The Author
Next Story